Regeneron beats quarterly profit estimates on eczema treatment strength

Regeneron Pharmaceuticals on
Thursday beat Wall Street estimates for third-quarter profit,
driven by strong demand for its eczema treatment Dupixent.
On an adjusted basis, the company...

Related Keywords

United States ,Bengaluru ,Karnataka ,India ,Roche Vabysmo ,Shounak Dasgupta ,Sriparna Roy ,Maju Samuel ,Reuters ,Regeneron Pharmaceuticals On ,Wall Street ,Markets ,